Imperial Chemical Industries Limited

Zeneca Limited

Ici Pharma

Cancer Research Campaign Technology Limited

Astrazeneca Ab

Other

Robert I Dowell

Philip John Burke

Anthony Brian Mauger

Caroline Joy Springer

David Waterson

Rodney B Hargreaves

David J Brown

Brian G Main

Philip N Edwards

Keith Oldham

Howard Tucker

Nicholas John Newcombe

Pierre A Bruneau

Laurent Francois Andre Hennequin

Maurice Raymond Verschoyle Finlay

Bernard Christophe Barlaam

David Huw Davies

Peter R Marsham

David Charles Blakey

David William Heaton

Craig W Thornber

Anthony Michael Slater

John Frederick Hennam

Malcolm Trevor Briggs

Christophe B Barlaam

Maurice R V Finlay

Rebecca J Cartwright

Susan Dines

Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

Metalloproteinase inhibitor compounds

Compounds

N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them

Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.

Chemical compounds

Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.

High purity N-(4-[N,N-bis(2-iodoethyl)amino]phenoscycarbonyl)-L-glutamic

Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalyzed reactions.

Process for antibody directed enzyme prodrug therapy

Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs substrates for carboxypeptidase G2 (CPG2) and yield more cytotoxic drugs than known products of CPG2 catalysed

Prodrugs for antibody directed enzyme prodrug therapy

The invention concerns a cyclic ether derivative of the formula I ##STR1## wherein Ar.sup.1 is optionally substituted phenyl, naphthyl or a 9- or 10-membered bicyclic heterocyclic moiety;

Pyran derivatives and their use as inhibitors of 5-lipoxygenase

The invention concerns an aryl derivative of the formula I, ##STR1## wherein Ar.sup.1 is optionally substituted phenyl, naphthyl or a heterocyclic moiety, and X.sup.1 is oxy, thio, sulphinyl, sulphonyl, difluoromethylene, imino, (1-4C)alkylimino or optionally substituted (1-4C)alkylene, or X.sup.1 is a group of the formula

Heterocyclic 5-lipoxygenase inhibitors

5-lipoxygenase inhibitors

Growing community of inventors

Congleton, United Kingdom

Robert I Dowell